NCT00833001已完成不适用
A Prospective, Multi-center Study to Evaluate the Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 126
- 试验地点
- 8
- 主要终点
- Pelvic Organ Prolapse Quantification (POP-Q) score
研究概览
简要总结
The purpose of this study is to evaluate the clinical performance of the PROLIFT system with a new lighter-weight mesh in repair of vaginal prolapse.
详细描述
Vaginal prolapse (a feeling of bulge in the vagina) may cause some distressing symptoms such as loss of control of the bowel or bladder, and may also cause problems with women's sex life. There are a number of different surgical procedures which are used to repair prolapse. Sometimes a mesh is placed in the pelvis to support the weakened tissues. There is a lot of research going on to find the most suitable type of mesh to repair vaginal prolapse. The GYNECARE PROLIFT + M* Pelvic Floor Repair system is similar to a mesh already used for this procedure called ULTRAPRO*, but is lighter in weight. Currently, ULTRAPRO* is only approved for use in hernia repair and is not licensed for gynecological procedures. This study will be the first clinical investigation of this mesh in vaginal prolapse.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage III or IV, suitable for surgical repair. Perineal repair, vaginal hysterectomy and/or mid urethral sling procedures for incontinence may be performed concurrently.
- •Age > or = 18 years.
- •Agrees to participate in the study, including completion of all study-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee / IRB approved informed consent.
排除标准
- •Additional surgical intervention for POP repair concurrent to the Gynecare Prolift+M procedure (e.g. paravaginal repair, sacrocolpopexy, colporrhaphy in a non-Gynecare Prolift+M treated compartment).
- •Previous repair of pelvic organ prolapse involving insertion of mesh.
- •Previous hysterectomy within 6 months of scheduled surgery.
- •Experimental drug or experimental medical device within 3 months prior to the planned procedure.
- •Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
- •Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
- •History of any pelvic radiation therapy.
- •History of chemotherapy within 6 months of the planned procedure.
- •Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma).
- •Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvodynia).
- •Nursing or pregnant or intends future pregnancy.
- •In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.
结局指标
主要结局
Pelvic Organ Prolapse Quantification (POP-Q) score
时间窗: 12 months post-procedure
次要结局
- Summary of treated compartment ICS POP-Q stage(3, 12, 24 and 36 months)
- Proportion of subjects with the leading edge within the hymen and without further re-intervention for POP(12, 24 and 36 months)
- Incidence of de novo prolapse (a post-operative prolapse)only in the untreated compartment, provided there was no pre-operative defect in that compartment(Procedure to 36 months)
- Mean scores and change from baseline in PFDI-20 scores, including sub scores (POPDI, CRADI and UDI(3, 12, 24 and 36 months)
- Mean scores and change from baseline in PFIQ-7, including sub-scores (POPIQ, CRAIQ and UIQ).(3, 12, 24 and 36 months)
- Days to return to normal activities (walking, driving, work, household activities and sexual intercourse)(1, 3, and 12 months)
- Assessment of sexual function using PISQ-12 (mean scores and change from baseline) in subjects sexually active at baseline(12, 24 and 36 months)
- Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareunia(Baseline to 36 months)
- Adverse Events(Procedure to 36 months)
- Determination of any exposures/erosions including location(Procedure to 36 months)
- Summary of International Continence Society (ICS) Stages(3, 24, and 36 months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Treatment for Stress and Mixed Urinary Incontinence and Vaginal Vault ProlapseUrinary Incontinence, StressMixed IncontinenceVaginal Vault ProlapseNCT00223106Medtronic - MITG467
终止
不适用
ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation for Prostate CancerProstate CancerNCT06375629EDAP TMS S.A.14
已完成
不适用
The Clinical Efficacy of RENASYS TOUCH NPWT System in the Management of Acute, Sub-acute and Chronic WoundsWound and InjuriesSurgical Wound DehiscenceNCT02565043Smith & Nephew, Inc.80
已完成
不适用
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and AlgorithmDiabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT03251079Senseonics, Inc.36
已完成
不适用
Reversible Portal Vein Embolization Before Major HepatectomyLiver RegenerationReversible Portal Vein EmbolizationNCT02945059Assistance Publique - Hôpitaux de Paris33